Drug
Sonrotoclax
Sonrotoclax: highest development phase Phase 2, developed by BeiGene. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- BeiGene
Trials
| Drug | Phase | Indication |
|---|---|---|
| sonrotoclax NCT06497062 | Phase 2 | Acute Myeloid Leukemia |
| Sonrotoclax NCT07885397 | Phase 1/2 | Myelodysplastic Syndromes, High Risk |
Latest
No recent events.
Follow Sonrotoclax on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.